Antagonism of lipopolysaccharide-induced blood pressure attenuation and vascular contractility

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 10, 2007, Pages 2170-2176

  Ehrentraut, S ^a   Frede, S ^b   Stapel, H ^a   Mengden, T ^a   Grohe C ^a   Fandrey, J ^b   Meyer, R ^a   Baumgarten, G ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Blood pressure; Sepsis; Toll like receptor 4 antagonism; Vascular contractility

Indexed keywords

ERITORAN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; METHYLISOTHIOUREA; N(G) NITROARGININE METHYL ESTER; PHENYLEPHRINE; THIOUREA DERIVATIVE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 3 O DECYL 2 DEOXY 6 O (2 DEOXY 3 O (3 METHOXYDECYL) 6 O METHYL 2 ((1 OXO 11 OCTADECENYL)AMINO) 4 O PHOSPHONOGLUCOPYRANOSYL) 2 ((1,3 DIOXOTETRADECYL)AMINO) 1 (DIHYDROXY PHOSPHATE)GLUCOPYRANOSE; 3-O-DECYL-2-DEOXY-6-O-(2-DEOXY-3-O-(3-METHOXYDECYL)-6-O-METHYL-2-((1-OXO-11-OCTADECENYL)AMINO)-4-O-PHOSPHONOGLUCOPYRANOSYL)-2-((1,3-DIOXOTETRADECYL)AMINO)-1-(DIHYDROXY PHOSPHATE)GLUCOPYRANOSE; CYTOKINE; DISACCHARIDE; DRUG DERIVATIVE; ENZYME INHIBITOR; LIPOPOLYSACCHARIDE, ESCHERICHIA COLI 0111 B4; MESSENGER RNA; NITRIC OXIDE; NOS2 PROTEIN, MOUSE; S METHYLISOTHIOPSEUDOURONIUM; S-METHYLISOTHIOPSEUDOURONIUM; SUGAR PHOSPHATE; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; C3H MOUSE; CARDIOVASCULAR SYSTEM; CONCENTRATION RESPONSE; CONTROL GROUP; CYTOKINE RELEASE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; EX VIVO STUDY; GRAM NEGATIVE BACTERIUM; HEART RATE; HEMODYNAMIC PARAMETERS; HYPOTENSION; INCUBATION TIME; MOUSE; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; STRAIN DIFFERENCE; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; VASCULAR RESISTANCE; VASCULAR RING; ANIMAL; AORTA; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; POINT MUTATION; TIME; VASOCONSTRICTION;

ANIMALS; AORTA; BLOOD PRESSURE; CYTOKINES; DISACCHARIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEART RATE; ISOTHIURONIUM; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C3H; MICE, MUTANT STRAINS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; POINT MUTATION; RNA, MESSENGER; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; SUGAR PHOSPHATES; TIME FACTORS; TOLL-LIKE RECEPTOR 4; VASOCONSTRICTION;

EID: 35148836026     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.146100     Document Type: Article

References (48)

1. Poeze M, Ramsay G, Gerlach H, Rubulotta F, Levy M. An international sepsis survey: a study of doctors' knowledge and perception about sepsis. Crit Care. 2004;8:R409-R413.
2. Kieft H, Hoepelman AI, Zhou W, Rozenberg-Arska M, Struyvenberg A, Verhoef J. The sepsis syndrome in a Dutch university hospital. Clinical observations. Arch Intern Med. 1993;153:2241-2247.
3. Baumgarten G, Knuefermann P, Nozaki N, Sivasubramanian N, Mann DL, Vallejo JG. In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of toll-like receptor-4. J Infect Dis. 2001;183:1617-1624.
4. Spronk PE, Zandstra DF, Ince C. Bench-to-bedside review: sepsis is a disease of the microcirculation. Crit Care. 2004;8:462-468.
5. Knuefermann P, Nemoto S, Misra A, Nozaki N, Defreitas G, Goyert SM, Carabello BA, Mann DL, Vallejo JG. CD14-deficient mice are protected against lipopolysaccharide-induced cardiac inflammation and left ventricular dysfunction. Circulation. 2002;106:2608-2615.
6. Baumgarten G, Knuefermann P, Schuhmacher G, Vervolgyi V, von Rappard J, Dreiner U, Fink K, Djoufack C, Hoeft A, Grohe C, Knowlton AA, Meyer R. Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemia. Shock. 2006;25:43-49.
7. Wong YN, Rossignol D, Rose JR, Kao R, Carter A, Lynn M. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J Clin Pharmacol. 2003;43:735-742.
8. Vallance P, Moncada S. Role of endogenous nitric oxide in septic shock. New Horiz. 1993;1:77-86.
9. Evans T, Carpenter A, Kinderman H, Cohen J. Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ Shock. 1993;41:77-81.
10. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999;162:3749-3752.
11. Parratt JR. Nitric oxide. A key mediator in sepsis and endotoxaemia? J Physiol Pharmacol. 1997;48:493-506.
12. Gunnett CA, Chu Y, Heistad DD, Loihl A, Faraci FM. Vascular effects of LPS in mice deficient in expression of the gene for inducible nitric oxide synthase. Am J Physiol. 1998;275:H416-H421.
13. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet. 1991;338:1557-1558.
14. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res. 1994;28:34-39.
15. Kim SS, Hwang JH, Choi CW, Shim JW, Chang YS, Park WS, Oh CK. Detrimental effects of N(omega) nitro-L-arginine methyl ester (L-NAME) in experimental Escherichia coli sepsis in the newborn piglet. J Korean Med Sci. 2003;18:637-640.
16. Robertson FM, Offner PJ, Ciceri DP, Becker WK, Pruitt BA Jr. Detrimental hemodynamic effects of nitric oxide synthase inhibition in septic shock. Arch Surg. 1994;129:149-155.
17. Minnard EA, Shou J, Naama H, Cech A, Gallagher H, Daly JM. Inhibition of nitric oxide synthesis is detrimental during endotoxemia. Arch Surg. 1994;129:142-147.
18. Fukatsu K, Saito H, Fukushima R, Inoue T, Lin MT, Inaba T, Muto T. Detrimental effects of a nitric oxide synthase inhibitor (N-omega-nitro-L- arginine-methyl-ester) in a murine sepsis model. Arch Surg. 1995;130:410-414.
19. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32:21-30.
20. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085-2088.
21. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res. 1977;41:19-26.
22. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, Rossignol DP. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther. 2003;304:1093-1102.
23. Hawkins LD, Christ WJ, Rossignol DP. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem. 2004;4:1147-1171.
24. Szabo C, Southan GJ, Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci U S A. 1994;91:12472-12476.
25. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
26. Julou-Schaeffer G, Gray GA, Fleming I, Schott C, Parratt JR, Stoclet JC. Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol. 1990;259:H1038-H1043.
27. Hoque AM, Marczin N, Catravas JD, Fuchs LC. Anesthesia with sodium pentobarbital enhances lipopolysaccharide-induced cardiovascular dysfunction in rats. Shock. 1996;6:365-370.
28. Hoque AM, Papapetropoulos A, Venema RC, Catravas JD, Fuchs LC. Effects of antisense oligonucleotide to iNOS on hemodynamic and vascular changes induced by LPS. Am J Physiol. 1998;275:H1078-H1083.
29. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie QW, Sokol K, Hutchinson N. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell. 1995;81:641-650.
30. Yang X, Coriolan D, Schultz K, Golenbock DT, Beasley D. Toll-like receptor 2 mediates persistent chemokine release by Chlamydia pneumoniae-infected vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2005;25:2308-2314.
31. Yang X, Murthy V, Schultz K, Tatro JB, Fitzgerald KA, Beasley D. Toll-like receptor 3 signaling evokes a proinflammatory and proliferative phenotype in human vascular smooth muscle cells. Am J Physiol. 2006;291:H2334-H2343.
32. Li H, He Y, Zhang J, Sun S, Sun B. Lipopolysaccharide regulates toll-like receptor 4 expression in human aortic smooth muscle cells. Cell Biol Int. 2007;31:831-835.
33. Lin FY, Chen YH, Tasi JS, Chen JW, Yang TL, Wang HJ, Li CY, Chen YL, Lin SJ. Endotoxin induces toll-like receptor 4 expression in vascular smooth muscle cells via NADPH oxidase activation and mitogen-activated protein kinase signaling pathways. Arterioscler Thromb Vasc Biol. 2006;26:2630-2637.
34. Faure E, Equils O, Sieling PA, Thomas L, Zhang FX, Kirschning CJ, Polentarutti N, Muzio M, Arditi M. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem. 2000;275:11058-11063.
35. Faure E, Thomas L, Xu H, Medvedev A, Equils O, Arditi M. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol. 2001;166:2018-2024.
36. Jones SB, Kotsonis P, Majewski H. Endotoxin enhances norepinephrine release in the rat by peripheral mechanisms. Shock. 1994;2:370-375.
37. Kilbourn RG, Jubran A, Gross SS, Griffith OW, Levi R, Adams J, Lodato RF. Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun. 1990;172:1132-1138.
38. Kilbourn RG, Griffith OW. Overproduction of nitric oxide in cytokine-mediated and septic shock. J Natl Cancer Inst. 1992;84:827-831.
39. Knowles RG, Salter M, Brooks SL, Moncada S. Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun. 1990;172:1042-1048.
40. Kato J, Tsuruda T, Kita T, Kitamura K, Eto T. Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol. 2005;25:2480-2487.
41. Bracken CP, Whitelaw ML, Peet DJ. The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses. Cell Mol Life Sci. 2003;60:1376-1393.
42. Frede S, Stockmann C, Freitag P, Fandrey J. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-kappaB. Biochem J. 2006;396:517-527.
43. Jougasaki M, Burnett JC Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci. 2000;66:855-872.
44. 2+ mobilization, in bovine aortic endothelial cells. J Biol Chem. 1995;270:4412-4417.
45. Zhang X, Hintze TH. cAMP signal transduction cascade, a novel pathway for the regulation of endothelial nitric oxide production in coronary blood vessels. Arterioscler Thromb Vasc Biol. 2001;21:797-803.
46. Fowler DE, Yang S, Zhou M, Chaudry IH, Simms HH, Wang P. Adrenomedullin and adrenomedullin binding protein-1: their role in the septic response. J Surg Res. 2003;109:175-181.
47. Hawkins LD, Ishizaka ST, McGuinness P, Zhang H, Gavin W, DeCosta B, Meng Z, Yang H, Mullarkey M, Young DW, Yang H, Rossignol DP, Nault A, Rose J, Przetak M, Chow JC, Gusovsky F. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. J Pharmacol Exp Ther. 2002;300:655-661.
48. Rossignol DP, Lynn M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res. 2002;8:483-488.